Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbon Nanoparticle Suspension Injection in Surgery for Papillary Thyroid Carcinoma
ChiCTR2300068502Phase 4Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2014
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Kanarine in papillary thyroid cancer (PTC) (4 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Parathyroid hormone (PTH), Number of lymph nodes detected and 2 more. Started Feb 2014; status: completed.
02
Drugs
Kanarine
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on ChiCTR2300068502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068502.